Liquid biopsy is a groundbreaking technique that enables the detection and analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other biomarkers associated with solid cancers, all from a simple blood sample.
In contrast to traditional biopsies, which necessitate invasive procedures to obtain tumor tissue, it is non-invasive and offers critical insights into tumor characteristics.
Non-invasive
Personalized medicine
Repeatability
Inexpensive
It provides a non-invasive approach to cancer monitoring, in contrast to traditional tissue biopsy methods.
It facilitates a personalized care strategy for each patient by identifying their unique antigenic and genetic profiles.
It can be done repeatedly to monitor the progress of the cancer at different timepoints through cancer evolution.
It is more cost-effective than traditional methods, significantly lowering the costs associated with cancer follow-up care.
Diagnostic assistance
Assessment of the treatment's effectiveness
Monitoring of minimal residual disease (MRD) following treatment
Early detection of cancer relapse
Liquid biopsy is intended to improve traditional diagnostic methods, such as tissue biopsies and imaging, by offering a non-invasive alternative. Its accessibility is especially beneficial in medically underserved regions, facilitating effective cancer monitoring even in resource-constrained settings.
Liquid biopsy can now be conducted effortlessly using our CYTO and MB kits, which are CE marked for routine clinical applications.
Are you interested in establishing a fundamental or clinical research project focused on circulating tumor cells (CTCs) or liquid biopsy ?
Share your project details with us, and we will be delighted to assist you in bringing it to fruition.
By Amira Mehtar, Janine Wechsler, Christophe Desterke, Julien Giron-Michel, Amira Bouzidi, Aude Burlion, Fawzia Louache, Samira Kahia-Tani , Georges Uzan, and Sina Naserian
